BioPartners GmbH and LG Life Sciences, Ltd. Present Positive Phase 3, Twenty-Four Months Efficacy and Safety Data for Sustained Release Recombinant Human Growth Hormone (LB03002) Given to Children with Growth Hormone Deficiency

Published: Sep 27, 2011

BAAR, Switzerland & SEOUL, South Korea--(BUSINESS WIRE)-- Biopartners GmbH and LG Life Sciences Ltd (LGLS) today presented positive Phase 3 results of 24 months efficacy and safety in children with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone (hGH), at the 50th annual meeting of the European Society for Paediatric Endocrinology (ESPE 2011) in Glasgow, Scotland.

A Phase 3 trial conducted globally, including Europe and the US, involving 167 paediatric patients with GHD demonstrated that LB03002, using LGLS’ proprietary delivery technology Biohydrix®, maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months who were switched from daily therapy. IGF-1 levels continued to increase toward the normal range in both groups during LB03002 treatment, a key marker of efficacy and safety in growth hormone therapy. LB03002 was well tolerated and demonstrated a sustained growth potential without excessive bone maturation.

Commenting on these new results Dr. Conrad Savoy, CEO of Biopartners GmbH said, “We are truly excited about the positive impact of this innovative once-a-week recombinant human growth hormone. These positive data further confirm previously presented positive data in children with GHD from a two year comparative trial versus daily growth hormone which was followed by a one year extension."

Dr. Hyi-Jeong Ji, VP of hGH Development at LGLS commented, “Based on this comprehensive set of data in GHD children together with 12 months of efficacy and safety in GHD adults, we believe this novel once-a-week hGH will offer a very attractive treatment modality to endocrinologists and their patients, leading to better adherence to long-term therapy, and ultimately, a more successful treatment outcome.”

LB03002 was originally developed by LGLS who granted Biopartners a license to further develop and market the product in Europe, Australia, New-Zealand and several other countries. LGLS retains rights in the rest of the world including North and South America, and most Asian countries including Korea, Japan, and China. An extension of this paediatric Phase 3 study is currently ongoing in India and Egypt.

About BioHydrix®

BioHydrix® is an LGLS proprietary sustained release (SR) technology with significant potential in the delivery of biologics. The unique hyaluronan microparticle matrix enables extended release of active substance.

About Biopartners

Established in 2000, Biopartners' aim is to be a leader in developing and commercializing innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet medical/patients' needs.

Biopartners seeks to offer safe and efficacious biopharmaceutical therapies. Its product portfolio covers the fields of endocrinology, multiple sclerosis and virology.

With its head office located in Switzerland, and an affiliate located in Germany, Biopartners is building an international network through a series of collaborations and partnerships. For more information, please visit the company’s website at:

About LG Life Science

LG Life Sciences, Ltd. is the leading Korean pharmaceutical company based in Seoul, Korea, committed to promoting the health and well-being of patients. The company’s key therapeutic areas include metabolic and cardiovascular diseases as well as infectious and liver diseases. LGLS seeks to continue developing global brand products such as Factive® (gemifloxacin) and expanding its marketing presence across the globe. For more information, please visit the company’s website at:


Biopartners GmbHDr Conrad SavoyE-mail: Conrad@biopartners.chTel: +41 41 766 2080LG Life Sciences, Ltd.Junhyung ParkE-mail: chunjae@lgls.comTel: +82 2 6924 3366

Back to news